Chardan Capital Thinks Spring Bank Pharmaceuticals Inc’s Stock is Going to Recover

By Carrie Williams

Chardan Capital analyst Taylor Feehley reiterated a Buy rating on Spring Bank Pharmaceuticals Inc (SBPHResearch Report) today and set a price target of $25. The company’s shares opened today at $4.60, close to its 52-week low of $3.58.

According to, Feehley has currently no stars on a ranking scale of 0-5 stars, with an average return of -29.7% and a 5.6% success rate. Feehley covers the Healthcare sector, focusing on stocks such as Evelo Biosciences Inc, Assembly Biosciences, and Seres Therapeutics.

Spring Bank Pharmaceuticals Inc has an analyst consensus of Strong Buy, with a price target consensus of $19.67, which is a 327.6% upside from current levels. In a report issued on July 18, Piper Jaffray also reiterated a Buy rating on the stock with a $10 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $15 and a one-year low of $3.58. Currently, Spring Bank Pharmaceuticals Inc has an average volume of 98.68K.

Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SBPH in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Spring Bank Pharmaceuticals, Inc. engages in discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. Its products are used for the treatment of viral infections, inflammatory diseases, and certain cancers.